Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'll explain it since you can't understand.
I am selling 3M with a .0121 average ($36,300)
I will recover 3M with a .0038 average (11,400)
- for a realized loss of $24900
My taxes owed on $24900 in profit would be 11700.
So for me to lose on this decision, not only would the PPS of LDSR need to hit .0121 by the end of January, but it would actually have to hit .016 considering my tax savings. It's just math. it's not personal. Why are you taking it so personal. If it does hit .016 before i buy back, then it was a bad bet. If not, I made a good decision.
I was just explaining 3M in sells to the board. Quit taking it so personal.
Just keep digging that hole, bud. You seem real comfortable.
hey tough guy... i was saying sorry in case i hurt momentum. Don't be such a grinch.
If everyone was so confident about this stock... it wouldn't be subpenny and you wouldn't get so butthurt over my simple little post. You're showing your weakness. Man up!
Sorry Longs. I am slowly selling off a few million to lock in LDSR losses and offset other gains. Didn't want to do it put the tax man is coming. I am trying to be gentle over the next week as to not hurt momentum. I plan to buy back in before Q1 is reported but it all depends on Jason at this point.
Merry Christmas!
Today's the day for NSX right?
Hello..... ?
No. only CRRVF
Can't wait for 12/19 so NSX can get the share price to .03!
I love the potential here as much as the next guy, but holding now makes no sense. I will be glad to chase it up the hill when the time comes and buy at higher levels than this, but I can't ignore the momentum and lack of interest.
I already sold for a loss to offset other gains. Still sitting on some of this garbage in my IRA so I am hoping for a pop so I can dump the rest. Is, was, and always will be a scam and everyone knows it. You may get a pop at some point. But this would have to do billions in volume to even get to a penny again. Float is huge and no one is gonna sit on this thing for long ever again. Just sell before January 8th when all those restricted shares get freed up. Once all the restricted shares are sold off, you know an RS is coming quick. IMO ....Good luck
I grabbed this at .0025 last march. Looks like I will be able to get it at .0025 again by next March. Pretty sad to see actually. I really liked the potential here but it seems that the endless bleed will not stop. I am still waiting to get back in. GLTA.
These are my posts after the last conference call. If I had written them today, they would look very similar. Without Q3 revs and an end to dilution, I will finally decide to add and average down before year end. At that point it will be in the trips and worth the risk. GLTA.
Post # 61851 of 73221
De Nova (of new) for a brand new device class is still issued a timeframe for review set at 120 FDA days. And who knows what "FDA days" means. I hope you are right. I am just being cautious with my expectations. Q1 rollout would be tremendous.
I should clarify. I think Q1 2019 is goal for rollout, but they will not start full force manufacturing until FDA approval is granted and they are able to fully start marketing. All IMO of course.
I am still thinking Q3 2019 because FDA approval is long. But I think they will move quick to enter the market once the approval is done.
DENVER, NC / November 9th, 2018 / CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector announces submission of the Carotid Stenotic Scan (CSS) to TUV Rheinland for electrical safety and EMC testing. TUV Rheinland is one of the leading providers of product safety certifications worldwide, covering an assortment of items such as medical devices, home appliances, audio/video products, medical products, textiles and telecommunication equipment. This testing is required for the CSS’s subsequent De Novo submission to the FDA for US market clearance and will show that the device is compliant with all IEC 60601-1 requirements. IEC 60601 is a series of technical standards for the safety and essential performance of medical electrical equipment, published by the International Electrotechnical Commission. First published in 1977 and regularly updated and restructured, IEC 60601-1 is widely accepted as the benchmark for electronic medical equipment. Additional information about TUV Rheinland can be found here (https://www.tuv.com/usa/en/).
Tony Robinson, CVR Medical Chief Operating Officer commented, “It feels good to have the CSS in the hands of TUV and progressing through one of the critical final steps necessary for our FDA submission. With the upcoming transition from IEC 60601-1 3rd Edition to 4th edition, a change which the CSS was already designed in compliance with, the queue to get devices into TUV substantially lengthened, exceeding what we originally allocated for an intended October FDA submission. This is pushing our timeline further back, but I have complete confidence in the engineers at CVR and the quality of the product they designed. With their focus on developing a product that is first and foremost safe, I believe that we will progress smoothly through the TUV testing schedule without delay. With the majority of our De Novo documentation finalized and current clinical trial numbers exceeding the requirements anticipated by our industry-leading regulatory consultants, we are still targeting an end of Q4 submission. However, this is contingent on external forces and is out of CVR’s control, though all key stakeholders are working tirelessly to expedite the process.
CVR also announces the intention to submit to Health Canada for a Canadian Medical Device License (MDL), which would provide approval for sales of the CSS into Canada, forthwith upon submitting to the FDA for market clearance. Obtaining the ability to distribute the CSS into Canada would open up one of the largest global economies, with diagnostic imaging representing 21% of their $6.7 billion medical device market.
Peter Bakema, CEO and Board Chairman, elaborates on the decision to launch into Canada in the near term, “It only makes sense that we continue our momentum with submitting to the FDA, leveraging both relational and geographic advantages. With the submission requirements mirroring most of the EU Technical dossier we will be able to advance the pace of global availability.”
About CVR Medical
CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan (CSS). The CSS device is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis which significantly increases the risk of stroke. CVR is currently in pivotal clinical trials in preparation for its planned submission to the FDA. CVR is led by an experienced and proven team of professionals with extensive healthcare, medical device, international expansion, regulatory and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com
ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Chairman
For further information contact:
Peter Bakema, CEO, President and Chairman
Email: info@cvrmed.com
or
Marc S. Lubow.
Vice President Capital Markets, Director / Investor Relations
marclubow@cvrmed.com
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Ditto and agree completely. The board is too ugly to hang out on, but long and not worried one bit. Thanks to all the longs for keeping up the good fight.
Good post. Got to love the potential. This will be as common as a blood pressure check on your annual exam.
Looks like someone dumped 25K shares at .24 and a few small buys walked it up. It is such a low volume and low float, any buying or selling can be volatile for movement. Lets hope the MMs keep the ask at .27 tomorrow.
IMO, this is a long-play, no-brainer for a 10 to 20 bagger in 12-24 months. But this isn't a sexy stock since there are not any swings to play and not enough volume to flip. It could still all fall apart and I lose my investment, but the deck is being stacked for success. I am perfectly happy holding and adding when I can. My average is .27 and I am fine being red on this one. We all still have plenty of time to accumulate shares before the uphill climb.
Kanter coming on is and end game strategy to get this over the goal line. Great News!
In My Opinion of course... GLTA
Leading Medical Device / Life Science / Healthcare Veteran Joel Kanter Joins Board of Directors of CVR Medical
DENVER, NC / October 15th, 2018 / CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) ("CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector announces that Mr. Joel Kanter has joined the Board of Directors. Mr. Kanter has served as President of Windy City, Inc. a privately held investment firm since July 1986. Mr. Kanter, is a veteran healthcare venture capitalist whose family office has financially backed numerous medical device, life science and healthcare companies throughout his 35-year career. Mr. Kanter has helped create billions in shareholder value, most notably; I-Flow which in 2009 was acquired by Kimberly-Clark for $324M, Clarisonic which in 2011 was acquired by L’Oréal for $525M, Prolor BioSciences which was acquired by OPKO Health in 2013 for USD $480M, Encore Medical which was acquired in 2006 by Blackstone for $860M, GranCare which in 1999 completed a $1.8B merger with Living Centers of America led by Apollo Management and Walnut Financial where he was Chief Executive Officer which was acquired in a transaction with Tower Hill Capital which resulted in an increase of $400M in shareholder value in 1999.
Mr. Kanter currently serves on the Board of Directors of two public companies including Magna-Labs, Inc. and MEDITE Cancer Diagnostics, Inc. and also serves on the Boards of several private concerns including Fibralign Corporation, First Wave Technologies, Orpheus Biosciences, Inc., Primal Therapies, Inc., and Serpin Pharma.
Mr. Kanter is also a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and of the Union Institute & University, the Country’s first Online University. He is also the current Board Chair of the Black Student Fund, and serves on the Kennedy Center’s National Committee on the Performing Arts.
Peter Bakema, Chairman and CEO of CVR Medical, states, “We are thrilled to welcome Joel to our Board of Directors and to have his rare breadth of experience and knowledge going forward. His track record of investment and acquisition success speaks to a visionary quality that we strive for at CVR. His involvement in moving our Carotid Stenotic Scan (CSS) device to market is another confident step towards providing a solution for a major sector of the healthcare industry beset with high costs and access barriers.”
Agree. I just read the entire filing at lunch. I am still holding 1M+ but I am deeply red and expecting it to get worse before it gets better. Still long and I fully understand the risk.
Business Highlights for the Third Quarter 2018
Secured the global technology, branding, and ongoing management rights to leading WordPress GDPR solution: The WordPress GDPR Framework
Formally completed the acquisition of Data443 by Landstar, Inc.
ClassiDocs™ integration with Citrix ShareFile verified as Citrix Ready and made available in the Citrix Ready Marketplace
Added Steven Mail and Philip Niedermair to Data443’s Strategic Advisory Board
Signed LOI to acquire Modevity’s enterprise cloud-based data storage, protection, and workflow automation platform, ARALOC™ and completed sales and marketing integration
Sponsored Headtechnology Group’s Headlight International 2018 conference in Bulgaria
Added to the default recommended Ripple XRP Ledger ecosystem’s Unique Node List (UNL)
Completed initial roadshow in New York City, spanning two weeks, which included two conferences and meetings with over 50 investors and investor groups
Formed strategic partnership with Online Business Systems and It4us Big Data Security Analysis to amplify Data443’s presence in North America and Brazil, respectively
ClassiDocs made available on the GOV.UK Digital Marketplace G-Cloud framework
Came to terms with Blue Citi on a restructuring of existing convertible notes to consolidate the notes into one agreement that includes more favorable terms, including the extension of the maturity date until March 2020, and the reduction on the discount on conversion from 25% to 10%, a very favorable reduction of ~36%
Terminated equity purchase agreement, resulting in the cancellation of $100,000 of common shares which were to be issued to Blue Citi, and reduced derivative liabilities by over $1,500,000 due to the related termination of the embedded beneficial conversion feature
"- Came to terms with Blue Citi on a restructuring of existing convertible notes to consolidate the notes into one agreement that includes more favorable terms, including the extension of the maturity date until March 2020, and the reduction on the discount on conversion from 25% to 10%, a very favorable reduction of ~36%
- Terminated equity purchase agreement, resulting in the cancellation of $100,000 of common shares which were to be issued to Blue Citi, and reduced derivative liabilities by over $1,500,000 due to the related termination of the embedded beneficial conversion feature"
This is my easiest investment.
I appreciate all the longs who post on this board and hold ground. Still hold enough of my early buys to be happy when this takes off. But this is the OTC investment I have the least concern about. This one just seems inevitable at this point. I assume I will be holding this in my portfolio for at least the next 5 years.
I do read and appreciate all the posts here and thank all who hold the line.
so much doom and gloom all the time... why bother here then
I'll just leave this here...
LinkedIn Top Startups 2018: The 50 most sought-after startups in the U.S
7. Ripple
Finance, modernized: Sending money between banks, across borders, remains stubbornly antiquated. Ripple uses blockchain technology to transform what had been a multi-day process into one completed in seconds. The 6-year-old startup now has more than 100 customers, including massive banks such as Santander and Standard Chartered; it added two new customers a week last quarter. | Global headcount: 250 | Headquarters: San Francisco | Ripple effect: While some blockchain companies are still “playing in the sandbox,” as Ripple tells LinkedIn, it’s focused on growth — it plans to hire another 75 people by year’s end.
The article is worth a read, a few of the "unicorn" companies appear remarkably similar to Data443, with much much higher valuations, Remember, Data443 Extends Significant Lead for Enterprise Security on Ripple XRP Ledger, Becomes Recommended Validator
you are still wrong. I didn't have a "limit" bid. I "slapped" the ask... please just stop whatever you think you are doing to "help".
The point is the bid could have been a buy at 38 but 2 hours later was filled as a sell at 37. Did you not understand that part of it? I think we all know what selling into the bid is. I was just pointing out the algorithm manipulation. I put it back on the ask at 39 and the MM will park under 39 to control it and hope i buckle and sell it back to him under 37.
I put in a bid of .038 for 50K shares at about 10:30AM EST. At the time the bis was 37 and the ask was 38. The ask immediately went to .039. I left it go and it finally filled at 12:54 (as part of a "sell" of 78500 shares at .037) My ask smack got filled lower and listed as a sell.
Early this morning I put 200k bids in on every tick from 80-70. None have been filled yet and i don't expect them to.
Thank you for the thoughtful and well mannered response.
While I am not here to bash or downplay how impressed I am with the future laid out, I just think the presentation was geared for investors and it missed the mark. I think that is pretty obvious by the drop in share price.
I have experience with investor pitch meetings and they are about fundamentals, revenue guidance, shareholder value expectations, business sector analysis, timelines, product implementation, and human equity. If you don't think the recently released financials will get picked apart by financial experts, you are a bit misguided. And if they don't have very good answers, they will receive no investment.
Matt will not put anything in writing and only asks investors to call him. But he will not address any financial questions in writing. That speaks volumes to me.
I am not in the IT world anymore but started my career there and got my education in network technologies and architecture. I graduated and had my MSCE back when it meant something. I have been in a different field for many years and I am no longer privy to the current complications of data governance and security. I will defer to your opinion on these.
I am not down on the company or the possibilities for the future. I just don't see any concern for creating shareholder value at the current stage of development. I am not selling and still hold 1M+ shares. I just have my own opinion of how yesterday went.
While I am long on DATA443 and holding discounted shares from the run up to .02, I don't know how anyone who plays in the pennies can qualify the CC yesterday as "real good" They didn't discuss any of the things that pink investors focus on. Shell Status, acquisition funding, toxic debt, note conversions, revs, etc. The free ride is over for this ticker, now they must deliver.
The most important thing you can do at this stage of the game is keep penny investors from leaving. And they dropped the ball in every way yesterday. If they don't care about the pinky players, that's fine too, but then why have the CC at all. Yesterday's powerpoint presentation made no sense to me and lacked intent and direction. It was more like a "good ole college try". And if they take that to institutional investors, they will get laughed out of the room. Frankly, I feel insulted by them not answering any questions that I know they were asked over and over again in emails. If they don't think that institutional investors are going to ask about derivative liabilities, debt conversion, funding, and so on... they are in for a rude awakening. And I also know this from experience.
I am not going to dump my holdings and plan to ride it out because I like the technology and potential of Jason and the team. But I will not invest in any more shares as of now. If they don't come correct with Q3 Revs and updated shell cleanup, this thing will be in bad shape at year end.
Always, just my opinion and I wish success for all involved, including invested shareholders. I hope I am very wrong and this was just a mis-step on the road to success.
CVR MEDICAL REPORTS POSITIVE INTERIM RESULTS FROM ONGOING PIVOTAL TRIAL WITH CSS DEVICE
CVR MEDICAL REPORTS POSITIVE INTERIM RESULTS FROM ONGOING PIVOTAL TRIAL WITH CSS DEVICE
New PR
CVR Medical Enlists JD Lymon Group to Provide Reimbursement and Study Design Support
VANCOUVER, BC / August 14th, 2018 / CVR Medical Corp. (CVM.V) (TSXV: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector has retained the services of Minneapolis-based medical device consulting firm, JD Lymon Group (www.jdlymon.com) to provide ongoing reimbursement guidance and to help support the company’s FDA submission of the Carotid Stenotic Scan (CSS) device for US market clearance by providing clinical trial design support.
With more than 70 combined years of medical device and pharmaceutical experience across the firm’s partners, JD Lymon focuses on accelerating market access through multidisciplinary strategies that address the complex interrelationship between policy, evidence, and practice in order to optimize the market position of emerging therapies. Specifically, JD Lymon will be guiding CVR through the complex and ever evolving reimbursement landscape. This will be done by designing the clinical trials in support of FDA submission, payer advocacy, and overall medical reimbursement coding needs.
CVR Medical Chief Operating Officer Tony Robinson stated, “As we prepare our FDA submission and eventual market release for the CSS device, the JD Lymon team will apply its insights and experience to help map out and articulate a reimbursement pathway to government and commercial payors.
Chris Lyle, Partner at JD Lymon, states, “We are honored to be selected by CVR to support their market access and study design needs. We understand the reimbursement challenges faced by small companies and emerging technologies. We look forward to a great collaboration and advancing the CSS System.”
About CVR Medical
It's hard to say. It might have just been someone wanting to play another runner and knowing he can come back here 6 months from now and probably get right back in between .25 and .30. Someone could have died and his children liquidated his accounts and bounced. Who is to say really. I am not that worried about it. This stock will bounce from .25-.30 for a while i bet.
If someone did get word of bad trials and dumped, why risk insider trading and felony charges for a few hundred grand. I wouldn't.
I don't know exactly. but it was quite a few. The biggest single sell i remember seeing was 119000 shares. It was lots of smaller 5000-35000 sells.
Like i mentioned, it really looked like a stop loss was triggered or someone just dumped at market and drove the price down. I managed to grab 5000K at .21 but that is all I had funds for.
This is the cheapest the stock has ever traded. I grabbed some more today.
Looks like someone dumped with a market order.
My best guess by looking at level 3 montage is someone had a sell at market order set at .249 or so and the stop loss triggered. Then the MM just walked it down to liquidate the shares.
There is no other reason that I can find such as news of information released.
Agreed. A nice startup at a penny seems like a good bet.